Evidence mapPaperPMID 37515308Full record

ArticleJournal of clinical laboratory analysis2023

Association between polymorphism rs2421943 of the insulin-degrading enzyme and schizophrenia: Preliminary report.

Laura Ambrozová, Tomáš Zeman, Vladimír Janout, Jana Janoutová, Jan Lochman, Omar Šerý

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Laura AmbrozováLaboratory of Neurobiology and Molecular Psychiatry, Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
Tomáš ZemanLaboratory of Neurobiology and Molecular Psychiatry, Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
Vladimír JanoutDepartment of Public Health, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Jana JanoutováDepartment of Public Health, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Jan LochmanLaboratory of Neurobiology and Molecular Psychiatry, Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
Omar ŠerýLaboratory of Neurobiology and Molecular Psychiatry, Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-6062-8997
Masaryk University · CZPalacký University Olomouc · CZ

Funding

Agentura Pro Zdravotnický Výzkum České Republiky NT14504Agentura Pro Zdravotnický Výzkum České Republiky NV18-04-00455Grantová Agentura České Republiky GP309/09/P361
6 · The paper itself

Abstract

backgroundInsulin-degrading enzyme (IDE) is an important gene in studies of the pathophysiology of type 2 diabetes mellitus (T2DM). Recent studies have suggested a possible link between type 2 diabetes mellitus (T2DM) and the pathophysiology of schizophrenia (SZ). At the same time, significant changes in insulin-degrading enzyme (IDE) gene expression have been found in the brains of people with schizophrenia. These findings highlight the need to further investigate the role of IDE in schizophrenia pathogenesis.

methodsWe enrolled 733 participants from the Czech Republic, including 383 patients with schizophrenia and 350 healthy controls. Our study focused on the single nucleotide polymorphism (SNP) rs2421943 in the IDE gene, which has previously been associated with the pathogenesis of Alzheimer's disease. The SNP was analyzed using the PCR-RFLP method.

resultsThe G allele of the rs2421943 polymorphism was found to significantly increase the risk of developing SZ (p < 0.01) when a gender-based analysis showed that both AG and GG genotypes were associated with a more than 1.55 times increased risk of SZ in females (p < 0.03) but not in males. Besides, we identified a potential binding site at the G allele locus for has-miR-7110-5p, providing a potential mechanism for the observed association.

conclusionOur results confirm the role of the IDE gene in schizophrenia pathogenesis and suggest that future research should investigate the relationship between miRNA and estrogen influence on IDE expression in schizophrenia pathogenesis.

Indexed as

Alzheimer DiseaseDiabetes Mellitus, Type 2InsulysinSchizophreniaFemaleGenotypeHumansMalePolymorphism, Single NucleotideInsulysincandidate gene analysesgenetic association studyinsulin-degrading enzyme (IDE)miRNAschizophrenic disordersingle nucleotide polymorphism (SNP)

Identifiers

PMID37515308
PMCPMC10492455
OpenAlexW4385377346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.